Abstract
Letters18 December 2012Adverse Effects of DabigatranPatricio A. Pazmiño, MD, PhDPatricio A. Pazmiño, MD, PhDFrom Nephrology, Internal Medicine and Hypertension Center, El Paso, TX 79902-3503.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-157-12-201212180-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:I read Radecki's article (1) with interest and agree with his concerns. Some of the potential harms stem from dabigatran's use for unapproved indications and in populations that have not been well-studied. The approval of dabigatran in the United States was based mostly on the results of the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial involving more than 18 000 patients (2). Unfortunately, this trial did not include patients with creatinine clearances less than 30 mL/min per 1.73 m2, which is common in the elderly and in patients with stage 4 or 5 chronic kidney disease.The ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
